Want to see HIMS full AI Analyst Report?
HIMS Stock Chart & Stats
$29.83
$1.42(5.06%)
At close: 4:00 PM EDT
$29.83
$1.42(5.06%)
Day’s Range― - ―
52-Week Range$13.74 - $65.30
Previous CloseN/A
Volume4.79M
Average Volume (3M)13.09M
Market Cap
$6.47B
Enterprise Value$8.74K
Total Cash (Recent Filing)$841.05M
Total Debt (Recent Filing)$1.55B
Price to Earnings (P/E)―
Beta2.54
Next Earnings
Nov 09, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding224,935,790
10 Day Avg. Volume10,218,227
30 Day Avg. Volume13,089,060
Financial Highlights & Ratios
PEG Ratio-33.04
Price to Book (P/B)13.50
Price to Sales (P/S)3.11
P/FCF Ratio98.76
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$32.90Price Target Upside10.29% Upside
Rating ConsensusHold
Number of Analyst Covering13
EPS Forecast (FY)-0.5
Revenue Forecast (FY)$3.20B
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthRapid revenue growth demonstrates expanding customer demand and effective scaling of the digital health platform. Continued growth across assortment, geographies, and subscribers can support broader fixed-cost leverage and strengthen the company’s competitive position over the next several quarters.
Positive Cash GenerationPositive operating and free cash flow provide internally generated funding for product expansion, customer acquisition, and platform investment. Maintaining cash generation despite a TTM net loss indicates that the core model can produce liquidity, although working-capital demands remain important to monitor.
International ExpansionInternational expansion adds geographic diversity and increases the addressable market beyond the company’s domestic base. Eucalyptus provides an established entry point, while further growth in Australia, the U.K., and other markets can create durable scale and cross-selling opportunities.
Bears Say
High LeverageThe sharp increase in debt relative to equity reduces financial flexibility and raises the burden placed on future cash generation. High leverage can constrain investment and capital-allocation choices, while making any prolonged period of inconsistent profitability more difficult to absorb.
Margin And Profitability PressureThe return to a TTM net loss, alongside sustained gross-margin compression, weakens earnings quality and makes the growth model less economically attractive. Greater mix exposure to branded weight loss and international revenue may keep margins below historical levels and delay dependable profitability.
Billing And Regulatory OverhangMonitoring by a major payments network creates a structural risk to billing operations and customer trust in an important growth category. Disputes may increase compliance costs, payment friction, or customer-acquisition challenges, while adding reputational pressure to the subscription model.
Hims & Hers Health News
HIMS FAQ
What was Hims & Hers Health’s price range in the past 12 months?
Hims & Hers Health lowest stock price was $13.74 and its highest was $65.30 in the past 12 months.
What is Hims & Hers Health’s market cap?
Hims & Hers Health’s market cap is $6.47B.
When is Hims & Hers Health’s upcoming earnings report date?
Hims & Hers Health’s upcoming earnings report date is Nov 09, 2026 which is in 63 days.
How were Hims & Hers Health’s earnings last quarter?
Hims & Hers Health released its earnings results on Aug 10, 2026. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.05 by -$0.32.
Is Hims & Hers Health overvalued?
According to Wall Street analysts Hims & Hers Health’s price is currently Undervalued.
Does Hims & Hers Health pay dividends?
Hims & Hers Health does not currently pay dividends.
What is Hims & Hers Health’s EPS estimate?
Hims & Hers Health’s EPS estimate is 0.06.
How many shares outstanding does Hims & Hers Health have?
Hims & Hers Health has 224,935,790 shares outstanding.
What happened to Hims & Hers Health’s price movement after its last earnings report?
Hims & Hers Health reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.05. Following the earnings report the stock price went down -3.966%.
Which hedge fund is a major shareholder of Hims & Hers Health?
Currently, no hedge funds are holding shares in HIMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hims & Hers Health Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$32.90 (10.29% Upside)
$32.90 (10.29% Upside)
Blogger Sentiment
Bullish
HIMS Sentiment 74%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 81.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $830.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-42.40%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
93.27%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Hims & Hers Health
Hims & Hers Health, Inc. operates a comprehensive digital health platform that seamlessly links individuals with licensed medical professionals for virtual consultations and ongoing care. Through its user-friendly websites and mobile app, the company delivers a diverse portfolio of health and wellness solutions directly to consumers. This includes access to recurring prescription medications, alongside a wide selection of over-the-counter drugs, devices, cosmetics, and dietary supplements. Its core focus areas are general wellness, sexual health, skincare, and hair care. Specific non-prescription offerings span categories such as: Wellness: encompassing items like vitamin C, melatonin, biotin, and collagen protein supplements. Skincare: including products such as moisturizers, serums, and face washes. Sexual Health: providing essentials like condoms, climax delay sprays and wipes, vibrators, and lubricants. Hair Care: offering specialized shampoos, conditioners, scalp scrubs, and topical treatments like minoxidil. Beyond direct sales, Hims & Hers also distributes health and wellness products via wholesale partnerships. The company's headquarters are located in San Francisco, California.
HIMS Company Deck
HIMS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed a constructive and growth-oriented outlook: strong revenue and subscriber growth, raised guidance, meaningful international scale from the Eucalyptus acquisition, and promising AI-driven engagement and efficiency gains. These positives are tempered by margin compression from mix shift toward branded weight loss and international sales, a GAAP loss driven by one-time costs, short-term negative cash flow in the quarter, and regulatory/legal uncertainties (FTC action and dependence on FDA rulemaking for peptides). Management highlighted liquidity actions and expects AI investments to pay back within 12–18 months, signaling confidence in the path to improved profitability.View all HIMS earnings summariesHIMS Revenue Breakdown
96.60% Online
3.40% Wholesale
HIMS Stock 12 Month Forecast
Average Price Target
$32.90
▲(10.29% Upside)
Technical Analysis
Ownership Overview
4.82% Insiders
14.65% Mutual Funds
11.78% Other Institutional Investors
47.91% Public Companies and Individual Investors